Navigation Links
The fantastic armor of a wonder snail
Date:1/19/2010

Deep within the Kairei Indian hydrothermal vent field, two-and-one-half miles below the central Indian Ocean, scientists have discovered a gastropod mollusk, whose armor could improve load-bearing and protective materials in everything from aircraft hulls to sports equipment.

Researchers at the National Science Foundation-supported Materials Research Science and Engineering Center at the Massachusetts Institute of Technology are studying the mollusk's physical and mechanical properties. A report, "Protection mechanisms of the iron-plated armor of a deep sea hydrothermal vent gastropod," appears this week in the Proceedings of the National Academy of Sciences.

The so-called "scaly-foot gastropod," has a unique tri-layered shell that may hold insights for future mechanical design principles. Specifically, it has a highly calcified inner layer, a thick organic middle layer. But, it's the extraordinary outer layer fused with granular iron sulfide that excites researchers.

The Kairei Indian vent field is a series of deep gashes in the planet's surface along a volcanic mountain chain below the Indian Ocean. There, researchers on an expedition discovered the never before seen snail in 1999.

"Hydrothermal vent fluids possess high concentration of sulfides and metals, but this mollusk is unique in that it incorporates materials plentiful to vent field into its shell structure," said MIT project leader Christine Ortiz at MIT's Department of Materials Science and Engineering. "We were interested in looking at the structure and properties of the individual layers and seeing how they behave mechanically," she said noting that the mollusk's organic inner layer is also interesting.

In particular researchers set out to discover what advantages the structure holds for protection against penetrating attacks from predators. Understanding this can give them new ideas for materials that may be used for cars, trucks and military applications.

To tes
'/>"/>

Contact: Bobbie Mixon
bmixon@nsf.gov
703-292-8070
National Science Foundation
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Fantastic photographs of fluorescent fish
2. Boston University biomedical engineers find chink in bacterias armor
3. When our protective armor shows weakness
4. Armored fish study helps strengthen Darwins natural selection theory
5. In the war against diseases, nerve cells need their armor
6. Researchers find chink in the armor of viral tummy bug
7. National Institutes of Health Secures Armory with Patent-Pending Technology
8. Making sure the wonder materials dont become the wonder pollutant
9. Wonderful cheese is all in the culture
10. The wonders of wine
11. Chemistry makes the natural wonder fabric -- wool -- more wonderful
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The fantastic armor of a wonder snail
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Associate Professor Catherine Pickering, said the Griffith study looked ... can be dispersed through horse manure. The findings have ... Restoration . "We reviewed 15 studies on seed ... North America, three from Australia and one study each ...
... , Nov. 7, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... its ongoing Phase 1 trial of KB004, an anti-EphA3 ... session at the 55 th American Society of ... trial of KB004 is a multi-center, dose-escalation study evaluating ...
... 7, 2013 The knowledge and skills required to change ... to those living with financial limitations. Competing demands on ... better diets. However, two researchers at the University ... the effects that three educational sessions might have on ...
Cached Biology News:Saddling up against the threat to our National Parks 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 3KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 4KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 53 'hands on' nutrition classes -- Enough to impact health behaviors in lower income women 2
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... Oct. 12 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced the close of previously reported agreements ... B Convertible Preferred Stock and warrants to purchase shares ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
... SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures ... the Editorial Board of Standard and Poor,s ("S&P") ... Records Market Access Program. Standard & Poor,s Corporation ... on U.S. and international public companies by investors ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
... Dawbarn and S.J. Allen (1995) ... by world authorities on current issues relating ... disease. Several major advances have been made ... this disease. Topics include molecular neuropathology through ...
Normal human serum, single donor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
biotin-4-fluorescein...
Biology Products: